Working Out the Genetic Risk for ADHD
Philadelphia, PA, December 7, 2016
Genetics play a strong part in the development of attention-deficit/hyperactivity disorder (ADHD), but the path from a gene to risk for the disorder has remained a black box to researchers. A new study in Biological Psychiatry suggests how the risk gene ADGRL3 (LPHN3) might work. ADGRL3 encodes the protein latrophilin 3, which regulates communication between brain cells. According to the study, a common variation of the gene associated with ADHD disrupts its ability to regulate gene transcription – the formation of mRNA from DNA that leads to expression of the gene.
Evidence for ADGRL3 in ADHD risk had already been stacked against it – common variants of the gene predispose people to ADHD and predict severity of the disorder. The study, led by Dr. Maximilian Muenke of the National Human Genome Research Institute in Bethesda, Maryland, brings scientists closer to understanding how ADGRL3 contributes to risk by providing functional evidence that implicates a transcription factor in the pathology of the disorder.
According to first author Dr. Ariel Martinez, the study is an effort to address limitations of existing ADHD medications that don’t work for all patients, and develop new medication targeting the protein encoded by the ADGRL3 gene.
“In this new era of genomics and precision medicine, the key to success lies in dissecting genetic contributions and involving some level of patient stratification,” Martinez said.
The researchers analyzed the ADGRL3 genomic region in 838 people, 372 of whom were diagnosed with ADHD. Variants in one particular segment within the gene, the transcriptional enhancer ECR47, showed the highest association with ADHD and with other disorders that commonly occur alongside ADHD, such as disruptive behaviors and substance use disorder.
ECR47 functions as a transcriptional enhancer to boost gene expression in the brain. However, the researchers found that a variation of ECR47 associated with ADHD disrupted ECR47’s ability to bind an important neurodevelopmental transcription factor, YY1 – an indication that the risk variant interferes with gene transcription.
In an analysis of postmortem human brain tissue from 137 control subjects, they also found an association between the ECR47 risk variant and reduced ADGRL3 expression in the thalamus, a key brain region for coordinating sensory processing in the brain. The findings link the gene to a potential mechanism for ADHD pathophysiology.
“The brain is extraordinarily complex. Yet we are starting to pull on the threads of that complex biology that reveal mechanisms through which disorders like ADHD might develop,” said Professor John Krystal, Editor of Biological Psychiatry. “In this case, Martinez and colleagues help us to understand how variation in the ADGRL3 gene might contribute to thalamic dysfunction in ADHD.”
Notes for editors
The article is "An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility," by Ariel F. Martinez, Yu Abe, Sungkook Hong, Kevin Molyneux, David Yarnell, Heiko Löhr, Wolfgang Driever, Maria T. Acosta, Mauricio Arcos-Burgos, and Maximilian Muenke (doi:10.1016/j.biopsych.2016.06.026). It appears in Biological Psychiatry, volume 80, issue 12 (2016), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or firstname.lastname@example.org. Journalists wishing to interview the authors may contact Ariel Martinez at email@example.com.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880